Epitalon
Epithalon
Grade C: Preliminary or limited human evidence
Key Takeaways
- Grade C: Preliminary or limited human evidence
- Not FDA approved: Not FDA-approved; no FDA review of this compound has established safety or efficacy.
- Compounding: The nomination to add Epitalon to the FDA 503A or 503B bulk-substances list was withdrawn; it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding.
Mechanism
Proposed to stimulate telomerase activity, resulting in telomere elongation in cell models; whether this mechanism operates similarly in vivo in humans is not established.
Evidence
Human intervention studies for epitalon exist but are limited to work from a single Russian research group (Khavinson and colleagues in St. Petersburg), including studies in retinitis pigmentosa patients and a multi-year mortality follow-up in older adults. These studies are single-group in design or lack independent replication by other investigators, which substantially limits confidence in their findings. No independently conducted, placebo-controlled trial by a separate research group has been published. Cell-line work has shown telomerase upregulation in human cells in vitro, but in vitro findings do not establish in vivo effects. Grade C reflects the existence of human intervention data while acknowledging the critical limitation that it comes from one group and has not been replicated. Note: the multi-year mortality follow-up often cited used epithalamin (a pineal extract), not synthetic epitalon; direct human evidence for synthetic epitalon is limited to smaller functional studies.
Safety and risks
Human safety data is limited to the single-group studies from the Khavinson group, which reported tolerability in those cohorts but cannot characterize uncommon or delayed harms at this sample scale and study design. The primary theoretical safety concern is the mechanism proponents themselves cite as the benefit: telomerase activation. Telomerase upregulation is a well-established feature of most cancer cells, and the implications of repeated exogenous stimulation of this pathway in people with cancer predisposition or occult malignancy are unknown and cannot be dismissed from animal data alone. Individuals with personal or family history of cancer, or known cancer-predisposing mutations, should treat this compound with particular caution pending independent safety data. Long-term human safety data are absent, and product purity from non-pharmaceutical sources is unverified.
Interactions
No human pharmacokinetic or interaction data available.
Federal compounding status
Nomination withdrawn (was Category 2) as of 2026-06-02.
This substance was nominated for the FDA 503A or 503B bulk-substances list and previously sat in the Category 2 (significant safety risk) group; the nomination was later withdrawn, so it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding. FDA source
Federal status only, from public FDA records. State pharmacy-board rules vary and are not covered here. This is regulatory reporting, not legal advice. All compounds.
Compounding legality
The nomination to add Epitalon to the FDA 503A or 503B bulk-substances list was withdrawn; it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding.
Sources
Epitalon is Not FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.
Last reviewed June 2, 2026 by PeptideGrids editorial team (independently audited).